Determinazione dei farmaci anticoagulanti orali diretti in regime di urgenza
Author:
Publisher
Edizioni Minerva Medica
Subject
Biochemistry, medical,Medical Laboratory Technology
Link
http://link.springer.com/content/pdf/10.1007/s13631-015-0091-5.pdf
Reference39 articles.
1. Eriksson BI, Dahl OE, Ahnfelt L et al. (2004) Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2:1573–1580
2. Agnelli G, Gallus A, Goldhaber SZ et al. (2007) ODIXa-DVT study investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 116:180–187
3. Mueck W, Becka M, Kubitza D et al. (2007) Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor—in healthy subjects. Int J Clin Pharmacol Ther 45:335–344
4. Blech S, Ebner T, Ludwig-Schwellinger E et al. (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386–399
5. Kazmi RS, Lwaleed BA (2011) New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol 72:593–603
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3